Amgen’s second quarter results outpaced Wall Street’s expectations, with management emphasizing strong demand for its ...

Amgen Inc. (NASDAQ:AMGN) shares are trading lower on Wednesday, despite the company reporting second-quarter results that ...

Amgen on Tuesday posted quarterly financial results that beat Wall Street expectations as a 9% increase in product sales ...

Amgen (AMGN) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the ...

Amgen AMGN delivered yet another strong quarterly performance. Its second-quarter 2025 earnings and sales beat estimates. The ...

Amgen (NASDAQ:AMGN) is set to release its earnings on Tuesday, August 5, 2025. Historically, Amgen's stock has shown a ...

In a report released today, from Oppenheimer maintained a Buy rating on Amgen, with a price target of $380.00. The company’s shares closed yesterday at $300.08. Elevate Your Inv ...

Amgen is also a component of the Dow Jones Industrial Average and Nasdaq-100 index, making its shares highly liquid. Lastly, the biotech's annualized yield now sits at an all-time high.

Dec 12 (Reuters) - Amgen Inc (AMGN.O) on Monday agreed to buy Horizon Therapeutics Plc (HZNP.O) in a deal valued at $27.8 billion, fortifying its rare diseases portfolio in the biggest buyout in ...

Amgen anticipates $500 million in annual pretax cost savings by the end of the third fiscal year after completion. The deal is expected to close in the first half of 2023, according to the companies.